Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Fate Therapeutics Inc.FATE · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required |
| Reliability | 0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| Peer failure rate | 1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $120M to $591M assetstotal assets $318.9M[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | short runway, thin data · fortress balance sheetnot computable: distress |
| Inputs computable | 5 of 14 |
| Graded from | filings received through Feb 26, 2026225 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $2.132026-10-08; market equity $255.2M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Feb 26, 2026; the document on sec.gov.
We are a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of off-the-shelf cellular immunotherapies to patients. We have pioneered a therapeutic approach that we generally refer to as cellular programming: we create and engineer human induced pluripotent stem cells (iPSCs) to incorporate novel synthetic controls of cell function; after the engineering step that incorporates multiple functional elements into the iPSCs, we generate a clonal master iPSC line for use as a renewable source of starting material for the manufacture of cell therapies; through the manufacturing process, we direct the fate of the clonal master iPSC line to produce our cell th...
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 49.0 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (8.0%) | [1,6-8] | (6.6%) | 49.0 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 31.5 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| liabilities and a nearby cover-page share count are required at 2026-06-30 | |||||||
| Altman Z double-prime | not computable | (0.31) | |||||
| one or more required annual facts are missing | |||||||
| Net debt to EBITDA | not computable | 1.82x | |||||
| EBITDA must exceed $100,000 | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| interest expense must exceed $100,000 | |||||||
| Current ratio | 5.79x | [9-10] | 2.96x | 31.5 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 70.9 | |||||||
| Revenue growth, three-year compound | (59.0%) | [2,11-13] | 10.0% | 96.6 | 415 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| one or more required annual facts are missing | |||||||
| Asset growth, three years | (23.3%) | [1,8,14-15] | 2.1% | 87.3 | 704 | 2025-12-31 | |
| Net share issuance, one year | 1.5% | [16-17] | 2.5% | 28.8 | 634 | 2026-02-19 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | 89.7% | 8.0% | 86 | hotter than 86 of 100 peers |
| Distance from 52-week high | (31.5%) | (31.4%) | 49 | closer to its high than 49 of 100 peers |
| EBIT to enterprise value | (61.2%) | (1.5%) | 11 | pricier than 89 of 100 peers |
| Free cash flow yield | (43.9%) | (1.0%) | 13 | pricier than 87 of 100 peers |
| Book value to price | 0.60 | 0.28 | 75 | pricier than 25 of 100 peers |
| Sales to price | 0.03 | 0.31 | 10 | pricier than 90 of 100 peers |
| Composite equity issuance, five years | 24.5% | 20.3% | 53 | more equity-funded than 53 of 100 peers |
| Relative strength against the sector, log excess return | 0.43 | (0.14) | 86 | ahead of 86 of 100 peers |
Inputs: market equity $255.2M; EBIT -$147.7M; free cash flow -$112.0M; book equity $153.4M; sales $6.6M; debt $18.5M; cash $32.4M[18].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (30.9%) | ✗ fail[6,8] |
| Operating cash flow above zero | -$106.1M | ✗ fail[7] |
| Return on assets improved | 5.9 pts | ✓ pass[6,8,14,19] |
| Operating cash flow exceeds net income | $30.2M | ✓ pass[6-7] |
| Long-term leverage fell | n/a[1,8,14] | |
| Current ratio improved | (179.2 pts) | ✗ fail[9-10,20-21] |
| No new shares issued | 1.5% | ✗ fail[16-17] |
| Gross margin improved | n/a | |
| Asset turnover improved | (1.2 pts) | ✗ fail[2,8,11,14] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $32.4M[3] |
| Operating cash flow, four quarters | -$101.9M[3,7,22-25] |
| Months of runway | 3.8 |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 57 |
| 10-Q received Aug 13, 2026 | |
| Median daily dollar volume | $3.3M |
| 63 sessions | |
| Days since newest grade input | 225 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $318.9M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $6.6M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $32.4M | 2026-06-30 | 2026-08-13 | 10-Q | filing · viewer · series |
| 4 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $190.5M | 2018-12-31 | 2021-02-24 | 10-K | filing · viewer · series |
| 5 | total debt | us-gaap:LongTermDebt | $18.5M | 2018-12-31 | 2019-03-05 | 10-K | filing · viewer · series |
| 6 | net income | us-gaap:NetIncomeLoss | -$136.3M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 7 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$106.1M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 8 | assets | us-gaap:Assets | $440.7M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 9 | current assets | us-gaap:AssetsCurrent | $208.7M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 10 | current liabilities | us-gaap:LiabilitiesCurrent | $36.1M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $13.6M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $63.5M | 2023-12-31 | 2025-03-05 | 10-K | filing · viewer · series |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $96.3M | 2022-12-31 | 2024-02-26 | 10-K | filing · viewer · series |
| 14 | assets | us-gaap:Assets | $506.2M | 2023-12-31 | 2025-03-05 | 10-K | filing · viewer · series |
| 15 | assets | us-gaap:Assets | $705.6M | 2022-12-31 | 2024-02-26 | 10-K | filing · viewer · series |
| 16 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 116,263,459 | 2026-02-19 | 2026-02-26 | 10-K | filing · viewer · series |
| 17 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 114,597,425 | 2025-02-25 | 2025-03-05 | 10-K | filing · viewer · series |
| 18 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 119,820,514 | 2026-08-06 | 2026-08-13 | 10-Q | filing · viewer · series |
| 19 | net income | us-gaap:NetIncomeLoss | -$186.3M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 20 | current assets | us-gaap:AssetsCurrent | $291.9M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 21 | current liabilities | us-gaap:LiabilitiesCurrent | $38.5M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$23.4M | 2026-06-30 | 2026-08-13 | 10-Q | filing · viewer · series |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$30.8M | 2026-03-31 | 2026-05-13 | 10-Q | filing · viewer · series |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$82.8M | 2025-09-30 | 2025-11-13 | 10-Q | filing · viewer · series |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$58.4M | 2025-06-30 | 2026-08-13 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.